Biotech VC Brandon Capital secures first close of $270m fund
Make us a preferred source
Make us a preferred source on Google
The news: Life sciences VC firm Brandon Capital has announced the first close of a $270 million fund to seed new local and global biotech startups.
The numbers: Brandon unveiled the first close of its sixth fund at the 2024 BIO International Convention in San Diego.
Since its establishment in 2007, Brandon has raised over $1 billion across five funds and completed over 60 investments in new therapeutic, medical device, and health tech companies.
The context: The Melbourne-based VC's sixth fund will continue to seed new Australian and New Zealand life sciences startups, as well as advance its expansion into international markets, particularly the UK, Europe and the US.
To support its investment strategy, Brandon has built a deal sourcing and company growth capability including offices in Australia, the UK, the US and New Zealand, as well as its own member network of over 50 medical research institutes and research hospitals.
What they said: Brandon's managing partner Chris Nave said: "We deeply appreciate our limited partners' continued trust in Brandon Capital and their ongoing recognition that the life sciences sector is an exciting and rewarding venture capital asset class".
"As stewards of this capital, it is a privilege to invest in companies with the capacity to deliver both financial and health returns," he said. "At Brandon, we partner with Australia’s brightest medical minds to support the translation of biomedical discoveries into companies developing new drugs, vaccines and medical devices."
The source: Brandon Capital media release
